Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-811X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Homoharringtonine, a clinically approved anti-leukemia drug, sensitizes tumor cells for TRAIL-induced necroptosis ; volume:13 ; number:1 ; day:29 ; month:4 ; year:2015 ; pages:1-16 ; date:12.2015
Cell communication and signaling ; 13, Heft 1 (29.4.2015), 1-16, 12.2015
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12964-015-0103-0
- URN
-
urn:nbn:de:101:1-2021081920275085209746
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:02 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Philipp, Stephan
- Sosna, Justyna
- Plenge, Johannes
- Kalthoff, Holger
- Adam, Dieter
- SpringerLink (Online service)
Other Objects (12)
Nanotoxicological profiles of clinically approved nanoplatforms
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
Induction, execution and clinical relevance of TNF- and TRAIL-induced necroptosis
Induction, execution and clinical relevance of TNf- and TRAIL-induced necroptosis
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
5-iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
Electrophoretic Delivery of Clinically Approved Anesthetic Drug for Chronic Pain Therapy
Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin
Nanotoxicological profiles of clinically approved nanoplatforms
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
Induction, execution and clinical relevance of TNF- and TRAIL-induced necroptosis
Induction, execution and clinical relevance of TNf- and TRAIL-induced necroptosis
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
5-iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
Electrophoretic Delivery of Clinically Approved Anesthetic Drug for Chronic Pain Therapy
Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules
miR-494 Sensitizes Gastric Cancer Cells to TRAIL Treatment Through Downregulation of Survivin
Nanotoxicological profiles of clinically approved nanoplatforms
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Activation of TNFR2 sensitizes macrophages for TNFR1-mediated necroptosis
TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis
Induction, execution and clinical relevance of TNF- and TRAIL-induced necroptosis
Induction, execution and clinical relevance of TNf- and TRAIL-induced necroptosis
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
5-iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling
Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis
Electrophoretic Delivery of Clinically Approved Anesthetic Drug for Chronic Pain Therapy
Zinc oxide nanoparticles conjugated with clinically-approved medicines as potential antibacterial molecules